Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(50.0%)
Phase 4
1(25.0%)
Phase 2
1(25.0%)
4Total
N/A(2)
Phase 4(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01941251Not ApplicableUnknown

Navigated αTMS in Treatment-resistant Schizophrenia

Role: lead

NCT02159001Not ApplicableUnknown

Electroconvulsive Therapy in Clozapine-resistant Schizophrenia

Role: lead

NCT02026947Phase 2Withdrawn

Sodium Benzoate for Treatment of Attenuated/Transient Psychosis. A Randomized Placebo-controlled Trial.

Role: lead

NCT00918021Phase 4Completed

Polypharmacy in Clozapine-resistant Schizophrenia

Role: lead

All 4 trials loaded